Skip to main content
Dryad

Enzyme-like nanoparticle engineered-mesenchymal stem cell secreting HGF promotes visualized therapy for idiopathic pulmonary fibrosis in vivo

Data files

Aug 22, 2024 version files 2.88 GB

Abstract

Stem cell therapy has emerged as a potential alternative treatment for idiopathic pulmonary fibrosis (IPF). However, its efficacy remains challenging due to factors such as ROS and inflammation in fibrotic lungs. Moreover, the distribution, migration, and survival of transplanted stem cells are still unclear, significantly impeding the clinical advancement of stem cell therapy. To tackle these challenges, we fabricate trimetallic-based nanocarriers (TBNCs) with enzyme-like activity and plasmid loading capabilities, aiming to efficiently eradicate ROS and facilitate delivery therapeutic genes and ultimately improve the therapeutic efficacy. Simultaneously, TBNCs function as an excellent CT contrast agent for tracking mesenchymal stem cells (MSCs), can improve the therapy by visualization-guiding. TBNCs was co-incubated with a hepatocyte growth factor plasmid gene to create TBNCs@pDNA, and then MSCs were modified with TBNCs@pDNA through endocytosis to generate engineered-MSCs, which demonstrate enhanced anti-oxidant and anti-inflammatory properties, thereby augmenting the therapeutic efficacy of MSCs. Finally, the in vivo CT tracking and therapy potential of engineered-MSCs is explored in IPF model mice. Overall, this study provides an efficient and forward-looking treatment approach for IPF and establishes a framework for a stem cell-based therapeutic system aimed at addressing lung disease.